Drugs / Autologous human bone marrow mononuclear fraction
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02616172 | Oct 2015 → Sep 2022 | sensorineural hearing loss disorder | James Baumgartner, MD | Suspended | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous human bone marrow mononuclear fraction | “Autologous human bone marrow mononuclear fraction (BMMF) will be harvested and given to children with bilateral moderate to severe sensorineural hearing loss.” NCT02616172 ↗ |
| Known as | BMMF | “Autologous human bone marrow mononuclear fraction (BMMF) will be harvested and given to children with bilateral moderate to severe sensorineural hearing loss.” NCT02616172 ↗ |
| Modality | Cell therapy | “One time administration of autologous bone marrow mononuclear cells intravenously” NCT02616172 ↗ |
| Route | Intravenous | “receive their autologous bone marrow mononuclear fraction (BMMF) intravenously” NCT02616172 ↗ |